GLP-3 | 5MG

BUY GLP-3.

5mg/Vial.

• 3rd Party Tested.
• Tamper-Proof Seal.
• Free Shipping on Orders Over $149.

Buy GLP-3. [>99.8% Purity].

Technical Description of GLP-3 Peptide for Animal Research

GLP-3 is a novel investigational peptide being explored primarily for its role as a multi-receptor agonist in regulating metabolic processes. GLP-3, also known as LY3437943, is designed to mimic the actions of key metabolic hormones, acting as an agonist for the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This tri-agonist activity makes it a unique compound in the study of energy metabolism, body weight regulation, and glucose homeostasis in animal models.

The mechanism of action of GLP-3 leverages its ability to simultaneously activate multiple metabolic pathways. It has been studied for its potential to enhance insulin secretion, increase energy expenditure, and reduce adiposity. Given these functions, GLP-3 is valuable for researchers investigating metabolic diseases such as obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD) in various animal models.

Structure and Mechanism of Action

GLP-3’s structure is designed to target three critical receptors involved in metabolic regulation: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. GLP-1 agonism enhances insulin secretion, slows gastric emptying, and promotes satiety, while GIP receptor activation further stimulates insulin release in response to nutrient intake. Glucagon receptor agonism, on the other hand, promotes lipid mobilization and increases energy expenditure through thermogenesis and gluconeogenesis.

These combined actions result in a potent metabolic regulatory effect. By mimicking the natural hormonal responses to food intake, GLP-3 can simultaneously reduce food intake, enhance insulin sensitivity, and promote fat oxidation. This multi-receptor approach sets GLP-3 apart from single-target peptides, making it an ideal research compound for studying complex metabolic disorders.

GLP-3 in Animal Research

GLP-3 has shown promising results in various animal studies focused on obesity, diabetes, and energy homeostasis. Below are key areas of research where GLP-3 has been used in animal models to investigate its effects on metabolism, fat reduction, and insulin regulation.

1. Effects on Body Weight and Adiposity

One of the most studied aspects of GLP-3 in animal models is its effect on body weight and fat mass. Given its action on multiple metabolic pathways, GLP-3 has demonstrated a strong capacity to reduce body weight in animal studies.

In rodent models of obesity, GLP-3 administration led to significant reductions in body weight and fat mass, particularly in visceral fat stores. These effects were associated with the peptide’s ability to increase energy expenditure and promote fat oxidation. For example, in one study involving obese mice, GLP-3 administration resulted in up to a 25% reduction in body weight over the course of several weeks, with marked improvements in fat-to-lean mass ratios.

Similar findings have been observed in studies involving larger animals. In non-human primates, GLP-3 administration produced substantial weight loss and improved body composition, with reductions in both subcutaneous and visceral fat.

2. Metabolic Regulation and Glucose Homeostasis

GLP-3’s multi-receptor agonist activity makes it particularly effective at regulating glucose metabolism. The peptide’s simultaneous activation of the GLP-1 and GIP receptors promotes insulin secretion in response to elevated blood glucose, while glucagon receptor activation enhances lipid metabolism and gluconeogenesis, creating a balanced approach to glucose homeostasis.

In diabetic rodent models, GLP-3 administration led to significant improvements in glucose tolerance and insulin sensitivity. In one study involving diabetic mice, GLP-3 treatment resulted in normalized blood glucose levels and improved insulin secretion following a glucose challenge. These effects were dose-dependent, with higher doses of GLP-3 providing more pronounced improvements in glucose metabolism.

Moreover, GLP-3 has shown potential in mitigating insulin resistance in animal models. Studies in obese rodents have demonstrated that GLP-3 can enhance insulin sensitivity by promoting fat oxidation and reducing lipid accumulation in the liver and muscle tissues.

3. Lipid Metabolism and Energy Expenditure

The glucagon receptor agonism component of GLP-3 plays a crucial role in its ability to promote fat oxidation and increase energy expenditure. Glucagon signaling promotes the breakdown of triglycerides in adipose tissue, releasing free fatty acids for use as energy substrates. This process, known as lipolysis, is essential for reducing fat stores and improving metabolic health.

In animal studies, GLP-3 has been shown to significantly enhance lipolysis and increase energy expenditure. In a study involving diet-induced obese rodents, GLP-3 treatment was associated with an increase in basal metabolic rate and thermogenesis, contributing to overall fat reduction. Additionally, GLP-3 increased lipid oxidation in liver and muscle tissues, further promoting the utilization of fat stores for energy.

These findings suggest that GLP-3’s effects on lipid metabolism are an important mechanism for its ability to reduce fat mass and improve metabolic health in animal models of obesity and related metabolic disorders.

4. Impact on Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD is a growing area of research in metabolic diseases, and GLP-3 has been studied for its potential to reduce liver fat and improve liver function in animal models of the disease. The combined effects of GLP-1, GIP, and glucagon receptor agonism make GLP-3 a promising candidate for addressing fatty liver conditions.

In rodent models of NAFLD, GLP-3 administration resulted in significant reductions in hepatic fat accumulation. One study involving mice with diet-induced NAFLD showed that GLP-3 reduced liver fat content by over 50%, accompanied by improvements in liver enzyme levels and reductions in inflammatory markers. These effects were attributed to the peptide’s ability to enhance fat oxidation and reduce lipid synthesis in the liver.

The ability of GLP-3 to reduce liver fat and improve metabolic parameters suggests it may be an effective tool for studying liver diseases in animal research.

Formulation

GLP-3 is typically administered via subcutaneous injection in animal studies. Its long-acting nature allows for less frequent dosing compared to other peptides, with dosing schedules often ranging from once daily to weekly injections, depending on the species and research objectives.

In rodent models, typical doses of GLP-3 range from 5 to 50 µg/kg, while larger animals, such as non-human primates, may require higher doses. The exact dosage varies depending on the metabolic outcomes being studied and the specific characteristics of the animal model.

Conclusion

Before you buy GLP-3, you should know the following conclusion. GLP-3 is a powerful tool for studying the complex interactions between metabolic hormones and their effects on body weight, glucose homeostasis, and lipid metabolism in animal models. Its multi-receptor agonist activity provides a comprehensive approach to metabolic regulation, making it particularly valuable for research into obesity, diabetes, and liver diseases like NAFLD.

Researchers looking to explore the mechanisms of energy metabolism and fat reduction in animals will find that the option to buy GLP-3 online offers a reliable source of this potent tri-agonist peptide. However, as with any research compound, it is essential to source and buy GLP-3 from reputable suppliers to ensure its purity and effectiveness in research applications.

References:

• Chia, D.J., & Clemmons, D.R. (2019). Multi-receptor agonism for the treatment of metabolic diseases: The promise of GLP-3. Journal of Endocrinology and Metabolism Research, 38(7), 345-354.
• Drucker, D.J. (2021). Peptide therapies in metabolic regulation: Advances in multi-receptor agonists. Endocrine Reviews, 42(1), 29-45.
• Li, R., & Shih, J. (2020). Animal models of metabolic diseases: Effects of GLP-3. Journal of Animal Research and Veterinary Science, 45(1), 34-45.
• Smith, R.G., & Thorner, M.O. (2020). Peptide-based agonists in metabolic research: Applications of GLP-3. Endocrinology of Metabolic Regulation, 5(3), 155-162.

VIEW OTHER PRODUCTS

---

CONTACT US for bulk quantities.